Transition Industries LLC and IFC announce agreement to develop net-zero world-scale methanol project in Sinaloa, Mexico
7.12.2023 21:44:00 EET | Business Wire | Press release
Transition Industries LLC announced at COP 28 that it has signed a Joint Project Development Agreement (JPDA) with the International Finance Corporation (IFC), a member of the World Bank Group, to jointly develop its Pacifico Mexinol project, a 6,145 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico.
When it initiates operations, Pacifico Mexinol is expected to be the largest single ultra-low carbon chemicals facility in the world - producing approximately 300,000 MT of green methanol from captured carbon and green hydrogen, and 1.8 million MT of blue methanol annually from natural gas with carbon capture.
Under the terms of the JPDA, the IFC will share a portion of the project development costs, provide substantial expertise to ensure compliance with the IFC Performance Environmental & Social Standards, and leverage its expertise to support the project financing. In return, the IFC has the right to invest in a pro rata percentage of the project’s common equity and lead the financing of at least 50% of the project’s debt.
Rommel Gallo, the CEO of Transition Industries, commented: “We are pleased to announce our JPDA with the IFC and proud to partner on this groundbreaking project. Together, we expect to set a new gold standard in ESG for the development of large industrial and chemicals projects that addresses climate change, sustainably manages natural resources such as water, and works in partnership with local communities to achieve shared value.”
Gallo continued: “We would like to extend a very special thank you to the Government of Mexico and its various secretariats. It is an honor to align with the Mexican government’s goals to promote development that is fair and equitable.”
Mr. Gallo thanked Sinaloa Governor Ruben Rocha Moya and his Secretary of Economy Javier Gaxiola Coppel, for their continued support and strong commitment to the success of Pacifico Mexico - expected to break ground in 2024. "We look forward to continuing to work with them in the coming years to promote Sinaloa as a hub for low-carbon investing.”
Gallo thanked various U.S. Government agencies for their continuing support and Ahome Municipal President Gerardo Vargas for his active leadership in promoting equitable investment in Northern Sinaloa.
Alfonso García Mora, IFC’s Vice President for Europe, Latin America and the Caribbean, said: “At IFC, we attract partners to invest alongside us as we provide capital to companies in developing countries, a process we call "mobilization." By mobilizing capital, we amplify the positive impact of our financing on the lives of people in developing countries. With this agreement, we contribute to the development of a project with the potential to reduce natural gas flaring, treat recycled wastewater, diversify Mexico’s chemicals capacity, increase exports and generate employment. At least 40% of the global production of methanol comes from coal. Decarbonizing methanol production is an imperative for IFC.”
Sinaloa State Governor Ruben Rocha Moya commented: “We are delighted to welcome Pacifico Mexinol to Sinaloa and are pleased to present our great state as a top destination for large investments that are socially and environmentally sustainable, generate well-paying jobs, and improve the social fabric of our communities.”
Pacifico Mexinol’s responsibility to sustainable resource management and its neighbors extends far beyond the ultra-low carbon production of methanol. The project has been engaging with local stakeholders for over four years, listening to local community members to understand their needs and concerns, resulting in innovative design solutions: the use of municipal wastewater to eliminate competition with local freshwater needs; no water removal from or discharge into the nearby bay – an important local ecosystem; and export of methanol through an existing port, requiring no dredging or additional infrastructure.
Pacifico Mexinol is expected to reach Final Investment Decision in 2024 and Commercial Operations in late 2027. The project is expected to generate on average 3,500 jobs during construction and up to 450 jobs during operations.
About IFC
IFC — a member of the World Bank Group — is the largest global development institution focused on the private sector in emerging markets. We work in more than 100 countries, using our capital, expertise, and influence to create markets and opportunities in developing countries. In fiscal year 2023, IFC committed a record $43.7 billion to private companies and financial institutions in developing countries, leveraging the power of the private sector to end extreme poverty and boost shared prosperity as economies grapple with the impacts of global compounding crises. For more information, visit www.ifc.org.
About Transition Industries
Transition Industries LLC, based in Houston, Texas, is a developer of world-scale net-zero carbon emissions methanol and hydrogen projects in North America to address climate change and promote environmental and social sustainability. For additional information about Pacifico Mexinol or Transition Industries, email inquiries@transitionind.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231207754479/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
